-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D9pRfq0MtfugzCoOARaoUA1o53iNTRY5kNTe+5rMwaXFcmN6MJPCPnx1ggCqJoso O/nJ1Mm1knMTd4jcEWMhZA== 0001079973-06-000716.txt : 20061227 0001079973-06-000716.hdr.sgml : 20061227 20061108082952 ACCESSION NUMBER: 0001079973-06-000716 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20061108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AspenBio Pharma, Inc. CENTRAL INDEX KEY: 0001167419 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 841553387 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1585 S. PERRY STREET CITY: CASTLE ROCK STATE: CO ZIP: 80104 BUSINESS PHONE: (303) 794-2000 MAIL ADDRESS: STREET 1: 1585 S. PERRY STREET CITY: CASTLE ROCK STATE: CO ZIP: 80104 FORMER COMPANY: FORMER CONFORMED NAME: ASPENBIO INC DATE OF NAME CHANGE: 20020213 CORRESP 1 filename1.htm

November 8, 2006


Via Facsimile and Federal Express

Ms. Mary K. Fraser
Division of Corporation Finance
United States Securities and Exchange Commission
450 Fifth Street, N.W.
Mail Stop 6010
Washington, D.C. 20549

  Re: AspenBio Pharma, Inc.
Form SB-2 Registration Statement
Filed September 20, 2006
File No. 333-137504

Ladies and Gentlemen:

Based on your oral confirmation that the Securities and Exchange Commission has no further comments on the Registration Statement, we are requesting acceleration of the Registration Statement.

      We acknowledge that:

  • should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the filing;

  • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve us from our full responsibility for the adequacy and accuracy of the disclosure in the filing; and

  • we may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

        We confirm that we are aware of our responsibilities under the Securities Act and under the Exchange Act as they relate to the public offering of securities specified in the Registration Statement. The undersigned hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “1933 Act”), that the effectiveness of the Registration Statement on Form SB-2 referred to above be accelerated so that it will be declared effective at 12:00 p.m., Eastern time, or as soon as practicable thereafter, on Friday, November 10, 2006. We understand that this request for acceleration is a confirmation of the fact that we are aware of our responsibilities under the federal securities laws.



Ms. Mary K. Fraser
November 8, 2006
Page 2

        We ask that you advise Theresa M. Mehringer, Esq. at 303-796-2626 upon the Registration Statement becoming effective. Please leave a voice mail message if you are unable to speak with Ms. Mehringer personally.

Respectfully submitted

ASPENBIO PHARMA, INC.


/s/ Jeffrey G. McGonegal
Jeffrey G. McGonegal, Chief Financial Officer


-----END PRIVACY-ENHANCED MESSAGE-----